Christopher Stroh

11.4k citations

78 papers · 8.0k indexed · 3 hit papers · h-index 28

Impact in

Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in ⓘ

Oncology 48
- Colorectal Cancer Treatments and Studies 25
- Lung Cancer Research Studies 14
Pulmonary and Respiratory Medicine 46
- Lung Cancer Treatments and Mutations 46
- Lung Cancer Diagnosis and Treatment 9

Co-authors: Klaus Schulze‐Osthoff (13 shared papers)Eric Van Cutsem (11 shared papers)Anatoly Makhson (2 shared papers)Sabine Tejpar (6 shared papers)Claus-Henning Köhne (2 shared papers)Philippe Rougier (2 shared papers)Johannes Nippgen (6 shared papers)Gunnar Folprecht (3 shared papers)
Journals: Journal of Clinical Oncology (24 papers)Cancer Research (6 papers)Journal of Thoracic Oncology (5 papers)Annals of Oncology (5 papers)Oncogene (4 papers)
Partner nations: Germany United States Spain

In The Last Decade

Christopher Stroh

75 papers receiving 7.8k citations

Hit Papers

align trajectories log scale

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer 2015 · 578 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 Journal of Clinical Oncology
2009 New England Journal of Medicine
2008 Journal of Clinical Oncology

Peers

Countries citing papers authored by Christopher Stroh

Since Specialization

Citations

This map shows the geographic impact of Christopher Stroh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Stroh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Stroh more than expected).

Fields of papers citing papers by Christopher Stroh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Stroh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Stroh. The network helps show where Christopher Stroh may publish in the future.

Co-authors

The 25 scholars most cited alongside Christopher Stroh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher Stroh Line = papers co-authored together Christopher Stroh links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 78 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer New England Journal of Medicine ·Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, J. Załuski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D’Haens, Tamás Pintér, Robert Lim, G. Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier Hit paper breakdown →	2009	2902
2	Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer Journal of Clinical Oncology ·Carsten Bokemeyer, Igor Bondarenko, Anatoly Makhson, J. T. Hartmann, Jorge Aparicio, Filippo de Braud, S. Donea, Heinz Ludwig, Gunter Schuch, Christopher Stroh, Anja H. Loos, Angela Zubel, P. Koralewski Hit paper breakdown →	2008	1245
3	Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer Journal of Clinical Oncology ·Eric Van Cutsem, Heinz‐Josef Lenz, Claus-Henning Köhne, Volker Heinemann, Sabine Tejpar, I. Melezínek, Frank Beier, Christopher Stroh, Philippe Rougier, J. Han van Krieken, Fortunato Ciardiello Hit paper breakdown →	2015	578
4	Activation and Caspase-mediated Inhibition of PARP: A Molecular Switch between Fibroblast Necrosis and Apoptosis in Death Receptor Signaling Molecular Biology of the Cell ·Marek Łoś, Malgorzata Mozoluk, Davide Ferrari, Anna Stępczyńska, Christopher Stroh, Andrea Renz, Zdenko Herceg, Zhao‐Qi Wang, Klaus Schulze‐Osthoff	2002	418
5	KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience Journal of Clinical Oncology ·Eric Van Cutsem, István Láng, G D’Haens, Vladimir Moiseyenko, J. Załuski, Gunnar Folprecht, Sabine Tejpar, O. Kisker, Christopher Stroh, P. Rougier	2008	281
6	Death by a thousand cuts: an ever increasing list of caspase substrates Cell Death and Differentiation ·Christopher Stroh, Klaus Schulze‐Osthoff	1998	237
7	Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis Oncogene ·Ingo H. Engels, Ania Stepczynska, Christopher Stroh, Kirsten Lauber, Christoph P. Berg, Ralf Schwenzer, Harald Wajant, Reiner U. Jänicke, Alan G. Porter, Claus Belka, Michael Gregor, Klaus Schulze‐Osthoff, Sebastian Wesselborg	2000	231
8	KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience Journal of Clinical Oncology ·Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann, Filippo de Braud, Constantin Volovăț, Johannes Nippgen, Christopher Stroh, İ. Çelik, P. Koralewski	2008	181
9	Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study Annals of Oncology ·Lisa Licitra, Ricard Mesı́a, Fernando Rivera, Éva Remenár, Ricardo Hitt, J. Erfán, Sylvie Rottey, Andrzej Kawecki, D. Zabolotnyy, Marco Benasso, Stephan Störkel, Stefanie Senger, Christopher Stroh, JB Vermorken	2010	178
10	Caspases: more than just killers? Trends in Immunology ·Marek Łoś, Christopher Stroh, Reiner U. Jänicke, Ingo H. Engels, Klaus Schulze‐Osthoff	2001	148
11	P2X7/P2Z Purinoreceptor-mediated Activation of Transcription Factor NFAT in Microglial Cells Journal of Biological Chemistry ·Davide Ferrari, Christopher Stroh, Klaus Schulze‐Osthoff	1999	137
12	Agonists of Proteinase-Activated Receptor-2 Stimulate Upregulation of Intercellular Cell Adhesion Molecule-1 in Primary Human Keratinocytes via Activation of NF-kappa B Journal of Investigative Dermatology ·Joerg Buddenkotte, Christopher Stroh, Ingo H. Engels, Corinna Moormann, Victoria Shpacovitch, Stephan Seeliger, Nathalie Vergnolle, Dietmar Vestweber, Thomas A. Luger, Klaus Schulze‐Osthoff, Martin Steinhoff	2005	110
13	Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design Drug Discovery Today ·Marek Łoś, Małgorzata Burek, Christopher Stroh, Konrad Benedyk, Hubert Hug, Andrzej Maćkiewicz	2003	93
14	The role of caspases in cryoinjury: caspase inhibition strongly improves the recovery of cryopreserved hematopoietic and other cells The FASEB Journal ·Christopher Stroh, U. Cassens, Ajoy Kumar Samraj, Walter Sibrowski, Klaus Schulze‐Osthoff, Marek Łoś	2002	91
15	Unique and overlapping substrate specificities of caspase-8 and caspase-10 Oncogene ·Ute Fischer, Christopher Stroh, Klaus Schulze‐Osthoff	2005	79
16	Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study Journal of Clinical Oncology ·Kenneth J. O’Byrne, Igor Bondarenko, Carlos Barrios, C. Eschbach, Uwe M. Martens, Yevhen Hotko, C. Kortsik, İ. Çelik, Christopher Stroh, Robert Pirker	2009	79
17	Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data) Journal of Clinical Oncology ·Sabine Tejpar, Marc Peeters, Yves Humblet, J. B. Vermorken, G De Hertogh, Wendy De Roock, Johannes Nippgen, Anja von Heydebreck, Christopher Stroh, Eric Van Cutsem	2008	75
18	Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer Journal of Clinical Oncology ·Annelies Debucquoy, Karin Haustermans, Anneleen Daemen, Selda Aydın, Louis Libbrecht, Olivier Gevaert, Bart De Moor, Sabine Tejpar, William H. McBride, Freddy Penninckx, Pierre Scalliet, Christopher Stroh, Soetkin Vlassak, Christine Sempoux, Jean‐Pascal Machiels	2009	75
19	Treatment outcome according to tumor ERCC1 expression status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab. Journal of Clinical Oncology ·Carsten Bokemeyer, Claus‐Henning Köhne, Igor Bondarenko, Anja von Heydebreck, H. Grote, Christopher Stroh, Heinz‐Josef Lenz	2013	71
20	Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats. Endocrinology ·George N. Cox, Martin J. McDermott, Erin Merkel, Christopher Stroh, S C Ko, Charles H. Squires, Thomas M. Gleason, D. A. Russell	1994	69

About Christopher Stroh

Christopher Stroh is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Hepatology and Radiology, Nuclear Medicine and Imaging, having authored 78 papers that have together received 8.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (46 papers), Colorectal Cancer Treatments and Studies (25 papers), Cancer Genomics and Diagnostics (16 papers), Lung Cancer Research Studies (14 papers), Lung Cancer Diagnosis and Treatment (9 papers), Cell death mechanisms and regulation (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers) and Liver physiology and pathology (7 papers). The work is most often cited by research in Oncology (5.6k citations), Hepatology (1.5k citations), Pathology and Forensic Medicine (1.7k citations), Cancer Research (1.2k citations) and Pulmonary and Respiratory Medicine (2.5k citations). Christopher Stroh has collaborated with scholars based in Germany, United States and Spain. Frequent co-authors include Klaus Schulze‐Osthoff, Eric Van Cutsem, Anatoly Makhson, Sabine Tejpar, Claus-Henning Köhne, Philippe Rougier, Johannes Nippgen, Gunnar Folprecht, J. Załuski and G. Bodoky. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Journal of Thoracic Oncology, Annals of Oncology and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact